Zobrazeno 1 - 10 of 89 pro vyhledávání: '"HW Auner"'
3
Akademický článek
Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.
Autor: Spertini C; Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland., Bénéchet AP; In Vivo Imaging Facility (IVIF), Department of Research and Training, Lausanne University Hospital and University of Lausanne, Lausanne, 1011, Switzerland., Birch F; Department of oncology UNIL-CHUV, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), 1011, Lausanne, Switzerland.; Ludwig Institute for Cancer Research Lausanne, 1015, Lausanne, Switzerland., Bellotti A; Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland., Román-Trufero M; Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland., Arber C; Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland.; Department of oncology UNIL-CHUV, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), 1011, Lausanne, Switzerland.; Ludwig Institute for Cancer Research Lausanne, 1015, Lausanne, Switzerland.; Faculty of Biology and Medicine, University of Lausanne, 1011, Lausanne, Switzerland.; Service of Immuno-oncology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland., Auner HW; Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland.; Faculty of Biology and Medicine, University of Lausanne, 1011, Lausanne, Switzerland., Mitchell RA; Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY, 40202, USA., Spertini O; Faculty of Biology and Medicine, University of Lausanne, 1011, Lausanne, Switzerland., Smirnova T; Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011, Lausanne, Switzerland. tatiana.smirnova@chuv.ch.
Publikováno v: Cell death discovery [Cell Death Discov] 2024 Mar 28; Vol. 10 (1), pp. 157. Date of Electronic Publication: 2024 Mar 28.
Zobrazit plný text záznamu
4
Akademický článek
Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30.
Autor: Mondal M; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London 82 Wood Lane London W12 0BZ UK e.tate@imperial.ac.uk., Cao F; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London 82 Wood Lane London W12 0BZ UK e.tate@imperial.ac.uk., Conole D; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London 82 Wood Lane London W12 0BZ UK e.tate@imperial.ac.uk., Auner HW; Department of Immunology and Inflammation, Imperial College London Du Cane Road London W12 0NN UK., Tate EW; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London 82 Wood Lane London W12 0BZ UK e.tate@imperial.ac.uk.
Publikováno v: RSC chemical biology [RSC Chem Biol] 2024 Mar 13; Vol. 5 (5), pp. 439-446. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).
Zobrazit plný text záznamu
5
Akademický článek
GLI1, a novel target of the ER stress regulator p97/VCP, promotes ATF6f-mediated activation of XBP1.
Autor: Almada LL; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Barroso K; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA; INSERM U1242, 'Oncogenesis, Stress, Signaling', Université de Rennes, Rennes, France; Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France., Sen S; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Toruner M; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Sigafoos AN; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Raja Arul GL; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Pease DR; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Vera RE; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Olson RLO; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA., Auner HW; Imperial College London, London, UK., Pedeux R; INSERM U1242, 'Oncogenesis, Stress, Signaling', Université de Rennes, Rennes, France; Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France., Iovanna JL; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, Marseille, France., Chevet E; INSERM U1242, 'Oncogenesis, Stress, Signaling', Université de Rennes, Rennes, France; Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France. Electronic address: eric.chevet@inserm.fr., Fernandez-Zapico ME; Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: fernandezzapico.martin@mayo.edu.
Publikováno v: Biochimica et biophysica acta. Gene regulatory mechanisms [Biochim Biophys Acta Gene Regul Mech] 2023 Jun; Vol. 1866 (2), pp. 194924. Date of Electronic Publication: 2023 Feb 25.
Zobrazit plný text záznamu
6
Akademický článek
Label-free nanoscale mapping of intracellular organelle chemistry.
Autor: Greaves GE; Experimental Solid State Group, Department of Physics, Imperial College London, London, UK. george.greaves15@imperial.ac.uk., Kiryushko D; Experimental Solid State Group, Department of Physics, Imperial College London, London, UK.; Department of Materials and London Centre for Nanotechnology, Imperial College London, London, UK., Auner HW; Department of Immunology and Inflammation, The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK., Porter AE; Department of Materials and London Centre for Nanotechnology, Imperial College London, London, UK., Phillips CC; Experimental Solid State Group, Department of Physics, Imperial College London, London, UK. chris.phillips@imperial.ac.uk.
Publikováno v: Communications biology [Commun Biol] 2023 May 31; Vol. 6 (1), pp. 583. Date of Electronic Publication: 2023 May 31.
Zobrazit plný text záznamu
7
Akademický článek
High patient satisfaction and increased physical activity following a remote multidisciplinary team multiple myeloma clinic.
Autor: Lecat CSY; University College London Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK. Catherine.lecat@nhs.net., Fisher A; University College London Institute of Epidemiology & Health Care, 1-19 Torrington Place, London, WC1E 7HB, UK., Atta M; Imperial College Healthcare NHS Trust, Hammersmith Hospital, 72 Du Cane Road, London, W12 0HS, UK., Camilleri M; University College London Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK., McCourt O; University College London Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK.; University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK., Land J; University College London Institute of Epidemiology & Health Care, 1-19 Torrington Place, London, WC1E 7HB, UK., Worthington S; University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK., Hart A; University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK., Daniel A; Imperial College Healthcare NHS Trust, Hammersmith Hospital, 72 Du Cane Road, London, W12 0HS, UK., Uddin I; University College London Institute of Epidemiology & Health Care, 1-19 Torrington Place, London, WC1E 7HB, UK., Roche C; University College London Institute of Epidemiology & Health Care, 1-19 Torrington Place, London, WC1E 7HB, UK., Auner HW; The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, Du Cane Road, London, W12 0NN, UK., Yong K; University College London Cancer Institute, 72 Huntley Street, London, WC1E 6DD, UK.
Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2023 Jan 21; Vol. 31 (2), pp. 127. Date of Electronic Publication: 2023 Jan 21.
Zobrazit plný text záznamu
8
Akademický článek
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
Autor: Royle KL; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK K.L.Royle@leeds.ac.uk., Coulson AB; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Ramasamy K; Radcliffe Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Quezada S; Department of Haematology, UCL Cancer Institute, London, UK., Drayson M; Clinical Immunology Service, Institute of Immunology and Immunotherapy, Medical School, University of Birmingham, Birmingham, UK., Kaiser M; Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK., Owen R; HMDS, St James's University Hospital, Leeds, UK., Auner HW; Department of Immunology and Inflammation, Imperial College London, London, UK.; Langmuir Centre for Myeloma Research, Imperial College London, London, UK., Cook G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK.; Leeds Cancer Centre, St James's University Hospital, Leeds, UK., Meads D; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Olivier C; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Barnard L; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Lambkin R; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Paterson A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Dawkins B; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Chapman M; Department of Haematology, University of Cambridge, Cambridge, UK., Pratt G; Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK., Popat R; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Jackson G; Northern Centre for Cancer Care, Freeman Hospital, Newcastle-Upon-Tyne, UK., Bygrave C; Department of Haematology, University Hospital of Wales, Cardiff, UK., Sive J; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., de Tute R; HMDS, St James's University Hospital, Leeds, UK., Chantry A; Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK., Parrish C; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Cook M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Bristol Myers Squibb, Boundry, Switzerland., Asher S; Department of Haematology, UCL Cancer Institute, London, UK., Yong K; Department of Haematology, UCL Cancer Institute, London, UK.
Publikováno v: BMJ open [BMJ Open] 2022 Nov 17; Vol. 12 (11), pp. e063037. Date of Electronic Publication: 2022 Nov 17.
Zobrazit plný text záznamu
9
Akademický článek
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
Autor: Kendall J; Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, West Yorkshire, UK J.E.Kendall@leeds.ac.uk., Hall A; Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, West Yorkshire, UK., Roberts S; Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, West Yorkshire, UK., Brown S; Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, West Yorkshire, UK., Boyd K; Department of Haematology, The Royal Marsden Hospital NHS Trust, London, UK.; Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Auner HW; Imperial College London, London, UK., Garg M; Leicester Royal Infirmary, Leicester, UK., Kaiser M; Department of Haematology, The Royal Marsden Hospital NHS Trust, London, UK.; Division of Genetics and Epidemiology, o The Institute of Cancer Research, London, UK.
Publikováno v: BMJ open [BMJ Open] 2022 Oct 26; Vol. 12 (10), pp. e062504. Date of Electronic Publication: 2022 Oct 26.
Zobrazit plný text záznamu
10
Akademický článek
Repeatability and test-retest reproducibility of mean apparent diffusion coefficient measurements of focal and diffuse disease in relapsed multiple myeloma at 3T whole body diffusion-weighted MRI (WB-DW-MRI).
Autor: ElGendy K; Imperial College Healthcare NHS Trust, London, United Kingdom.; The Department of Surgery and Cancer, Imperial College, London, United Kingdom., Barwick TD; Imperial College Healthcare NHS Trust, London, United Kingdom.; The Department of Surgery and Cancer, Imperial College, London, United Kingdom., Auner HW; The Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom., Chaidos A; The Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.; Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom., Wallitt K; Imperial College Healthcare NHS Trust, London, United Kingdom., Sergot A; Imperial College Healthcare NHS Trust, London, United Kingdom., Rockall A; Imperial College Healthcare NHS Trust, London, United Kingdom.; The Department of Surgery and Cancer, Imperial College, London, United Kingdom.
Publikováno v: The British journal of radiology [Br J Radiol] 2022 Sep 01; Vol. 95 (1138), pp. 20220418. Date of Electronic Publication: 2022 Jul 28.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje